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Abstract
A structurally unique hydrophobic compound, biyouyanagin A, was isolated from the MeOH extract
of the leaves of Hypericum chinense L. var. salicifolium. The structure of biyouyanagin A was
elucidated on the basis of spectroscopic evidence. Biyouyanagin A showed a significant activity
against HIV and inhibited cytokine production.
The recent widespread interest in the antidepressant activity of Hypericum perforatum (St.
John’s wort) has inspired the investigation of secondary metabolites from other Hypericum
species.1 The genus Hypericum, which are distributed widely in temperate regions, have been
used as traditional medicines in various parts of the world. In Japan, H. chinense L. var.
salicifolium (Biyouyanagi in Japanese) is used as a folk medicine for treatment of female
disorders.2
Antibacterial acylphloroglucinols and spirolactones were also isolated from this species.3 As
a part of a program to discover new bioactive natural products from plants, we have examined
the MeOH extract from the leaves of H. chinense and isolated a unique hydrophobic compound
named biyouyanagin A, which contains sesquiterpene, cyclobutane, and spirolactone moieties.
Biyouyanagin A showed a significant activity against HIV and inhibited cytokine production.
In this paper, we report isolation, structural elucidation, and biological evaluation of
biyouyanagin A.
Dried leaves of H. chinense L. var. salicifolium (1.48 kg) were extracted with MeOH. The
MeOH extract (632.7 g) was partitioned with n-hexane and H2O, and the n-hexane fraction
(92.6 g) was subjected to repeated column chromatography to give biyouyanagin A.
Biyouyanagin A (1) was obtained as a colorless oil, [α]D –240.0 (CHCl3, c 0.5). The IR
spectrum of 1 showed absorption bands of two carbonyl groups (1792, 1743 cm−1). The 1H
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NMR showed the presence of a benzene ring [δH 7.26–7.37 (5H, m)], a 1-substituted ethylene
moiety [δH 5.24 (1H, dd, J = 17.6, 11.2), 4.80 (1H, d, J = 11.2), 4.62 (1H, d, J = 17.6)], two
olefinic protons [δH 5.46 (1H, m), 5.11 (1H, brt, J = 5.6)], one oxygenated methylene group
[δH 4.71, 3.98 (each 1H, d, J = 8.8)], five methines, three methylenes, and five methyls. The
HRFABMS gave a quasimolecular ion peak at m/z 475.2911 ([M + H]+, calcd 475.2848)
suggesting the molecular formula of C31H38O4. The 13C NMR spectral data, including DEPT
spectra, were in good agreement with the above analysis (Table 1).
The 1H–1H COSY spectrum of 1 showed the following correlations: H3-25–H-24–H2-26–
H2-27–H-28; H-20–H2-21–H-22–H-17–H-18. The structure of partial unit A (sesquiterpene
unit, Figure 1) was indicated by the following long-range correlations in the HMBC spectrum:
H3-30 and -31 with C-28, -29; H3-25 with C-22, -24, -26; H3-23 with C-18, -19, -20; H-17
with C-18, -19, -21, -22, -24; and H-18 with C-17, -19, -20, -23.
The remaining 1H and 13C NMR signals of 1 were compared with those of hyperolactone C.
4 These data showed good agreement except for the signals of H-6 [δH 3.16 (1H, dd, J = 6.0,
1.2) in 1 vs 5.99 (1H, s) in hyperolactone C, C-5 (δC 209.6 vs 196.6), C-6 (δC 51.9 vs 100.3),
C-7 (δC 89.7 vs 187.3), and C-11 (δC 139.6 vs 127.7)]. In 1, the long-range correlations of H-6
with C-4, -5, -11 were observed in the HMBC spectrum. These results clearly indicated that
1 has a saturated C-6/C-7 bond (methine carbon and a quaternary carbon, respectively) rather
than the double bond in hyperolactone C. Thus, the structure of partial unit B (spiro-lactone
unit, Figure 1) was elucidated.
The connections of units A (sesquiterpene) and B (spiro-lactone) were established on the basis
of the following key correlations: H-6 with H-17 (1H-1H COSY); H-6 with C-17, -18, -22,
H-17 with C-5, -6, -7, H-18 with C-6, -7 (HMBC). Thus, the direct connections between C-6
and C-17, C-7 and C-18 formed a cyclobutane ring.
The relative configuration was established from the following NOE correlations: H-6 with
H-17, -22, and aromatic protons; H-17 with H-18, -22; H3-10 with aromatic protons. Thus, the
structure of 1 was elucidated (Figure 2).
Our postulated biosynthetic pathway of 1 from the related sesquiterpene and spirolactone is
shown in Scheme 1.
In the search for anti-HIV natural products, various coumarins, terpenoids, and
phloroglucinols5 have been reported to have anti-HIV activity. Accordingly, we evaluated anti-
HIV activity of this novel compound. Compound 1 inhibited HIV replication in H9
lymphocytes with an EC50 value of 0.798 μg/mL and uninfected H9 cell growth with IC50
values of > 25 μg/mL, giving a calculated therapeutic index (TI) value of >31.3 (Table 2).
Thus, 1 can be regarded as a promising new anti-HIV agent with a unique structure and merits
further evaluation and analogue design.
Furthermore, we examined the effect of 1 in LPS-induced cytokine production, and it markedly
inhibited the LPS-induced production of IL-10, IL-12, and TNF-α (Table 3). These data suggest
that 1 is a strong inhibitor for cytokines and is worthy of further investigation.
Acknowledgements
This investigation was supported in part by Grant No. AI-33066 from the National Institute of Allergy and Infectious
Diseases (NIAID) awarded to K.H.L.
Tanaka et al. Page 2














1. Cardellina JH II. J Nat Prod 2002;65:1073–1084. [PubMed: 12141880]
2. Murakami K. Tokushima-ken Yakusouzukan 1984:102–103.
3. (a) Nagai M, Tada M. Chem Lett 1987:1337–1340. (b) Tada M, Nagai M. Chem Lett 1989:683–686.
(c) Aramaki Y, Chiba K, Tada M. Phytochemistry 1995;38:1419–1421.
4. Aramaki Y, Chiba K, Tada M. Phytochemistry 1995;38:1419–1421.
5. (a) Lee, Thomas TY.; Kashiwada, Y.; Huang, L.; Snider, J.; Cheng, YC.; Lee, KH. Bioorg Med Chem
1994;2:1051–1056. [PubMed: 7773621] (b) Gustafson KR, Cardellina JH, McMahon JB, Gulakowski
RJ, Ishitoya J, Szallasi Z, Lewin NE, Blumberg PM, Weislow OS, Beutler JA, Buckheit RW Jr, Cragg
GM, Cox PA, Barder JP, Boyd MR. J Med Chem 1992;35:1978–1986. [PubMed: 1597853] (c) Fujioka
T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Balls LM, Jing JB, Jazen WP, Chen IS, Lee KH. J Nat
Prod 1994;57:243–247. [PubMed: 8176401] (d) Fuller RW, Blunt JW, Boswell JL, Cardellina JH II,
Boyd MR. J Nat Prod 1999;62:130–132. [PubMed: 9917299]
Tanaka et al. Page 3














Partial structures of 1.
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Table 1
NMR Data for 1a
position 13C (δC)
1H (δH) HMBC (13C no.)
1 118.4 4.80 (1H, d, 11.2)
4.62 (1H, d, 17.6)
3




6 51.9 3.16 (1H, dd, 6.0, 1.2) 4, 5, 11, 17, 18, 22
7 89.7
8 171.6
9 73.7 4.71 (1H, d, 8.8)
3.98 (1H, d, 8.8)
3, 4, 8, 10
10 20.1 1.31 (3H, s) 2, 3, 4, 9
11 139.6
12 125.9 7.37–7.26 (1H, m) 7
13 127.7 7.37–7.26 (1H, m)
14 127.8 7.37–7.26 (1H, m)
15 127.7 7.37–7.26 (1H, m)
16 125.9 7.37–7.26 (1H, m) 7
17 35.9 3.01 (1H, ddd, 8.4, 6.6, 6.6) 5, 6, 7, 18, 19, 21, 22, 24
18 50.3 3.49 (1H, d, 8.4) 6, 7, 17, 19, 20, 23
19 131.4
20 123.9 5.46 (1H, m)
21 23.5 2.09 (1H, m)
1.99 (1H, m)
22 38.8 1.73 (1H, m) 6,
23 21.7 1.02 (3H, d, 1.2) 18, 19, 20
24 35.1 1.46 (1H, m)
25 16.8 0.83 (3H, d, 6.4) 22, 24, 26
26 35.0 1.45 (1H, m)
1.20 (1H, m)
24, 27, 28
27 25.9 2.02 (1H, m)
1.94 (1H, m)
28 124.6 5.11 (1H, brt, 5.6) 27, 30, 31
29 131.4
30 25.7 1.70 (3H, d, 1.2) 28, 29, 31
31 17.7 1.61 (3H, s) 28, 29, 30
a
Measured in CDCl3. Coupling constants given (J, Hz) in parentheses.
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Table 2
Anti-HIV Activity of 1
compd IC50 (μg/mL) EC50 (μg/mL) TI
biyouyanagin A (1) >25 0.798 31.3
AZT 500 0.0021 238, 738













Tanaka et al. Page 9
Table 3
Inhibitory Effects for Cytokine Release of 1a
cytokine production ratio
compd IL-10 IL-12 TNF-α
biyouyanagin A (1) 0.03 0.02 0.48
prednisolone 0.14 0.24 0.48
a
PBMCs were treated with lipopolysaccharide (LPS) in the presence of 1 (10 μg/mL). Prednisolone (0.3 μg/mL) was used as a reference sample.
Data were expressed as ratios to cytokine production induced by LPS.
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